BR112014027333A2 - composição, métodos de tratamento ou melhora, de prevenção, e, de diagnóstico de uma condição prejudicial que está associada com o teor elevado de sulfato de heparano em um indivíduo que foi o receptor de um órgão, tecido ou células transplantados - Google Patents

composição, métodos de tratamento ou melhora, de prevenção, e, de diagnóstico de uma condição prejudicial que está associada com o teor elevado de sulfato de heparano em um indivíduo que foi o receptor de um órgão, tecido ou células transplantados

Info

Publication number
BR112014027333A2
BR112014027333A2 BR112014027333A BR112014027333A BR112014027333A2 BR 112014027333 A2 BR112014027333 A2 BR 112014027333A2 BR 112014027333 A BR112014027333 A BR 112014027333A BR 112014027333 A BR112014027333 A BR 112014027333A BR 112014027333 A2 BR112014027333 A2 BR 112014027333A2
Authority
BR
Brazil
Prior art keywords
heparan sulfate
methods
recipient
diagnosis
tissue
Prior art date
Application number
BR112014027333A
Other languages
English (en)
Inventor
V Brennan Todd
Yang Yiping
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of BR112014027333A2 publication Critical patent/BR112014027333A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02007—Heparin lyase (4.2.2.7), i.e. heparinase I
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1 / 1 resumo “composiã‡ãƒo, mã‰todos de tratamento ou melhora, de prevenã‡ãƒo, e, de diagnã“stico de uma condiã‡ãƒo prejudicial que estã� associada com o teor elevado de sulfato de heparano em um indivã�duo que foi o receptor de um ã“rgãƒo, tecido ou cã‰lulas transplantadosâ€� a presente descriã§ã£o prov㪠mã©todos de identificaã§ã£o de rejeiã§ã£o a transplantes atravã©s do uso de sulfato de heparano como um biomarcador. o mã©todo tambã©m compreende o tratamento e/ou a prevenã§ã£o da rejeiã§ã£o do transplante em um indivã­duo, compreendendo a administraã§ã£o ao indivã­duo de um inibidor de sulfato de heparano, assim tratando e/ou prevenindo o desenvolvimento de lesã£o imune-mediada apã³s o transplante.
BR112014027333A 2012-05-01 2013-05-01 composição, métodos de tratamento ou melhora, de prevenção, e, de diagnóstico de uma condição prejudicial que está associada com o teor elevado de sulfato de heparano em um indivíduo que foi o receptor de um órgão, tecido ou células transplantados BR112014027333A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261641043P 2012-05-01 2012-05-01
US201261660914P 2012-06-18 2012-06-18
PCT/US2013/039086 WO2013166163A1 (en) 2012-05-01 2013-05-01 Compositions and methods for heparan sulfate as a biomarker for transplant rejection

Publications (1)

Publication Number Publication Date
BR112014027333A2 true BR112014027333A2 (pt) 2017-07-18

Family

ID=49514856

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014027333A BR112014027333A2 (pt) 2012-05-01 2013-05-01 composição, métodos de tratamento ou melhora, de prevenção, e, de diagnóstico de uma condição prejudicial que está associada com o teor elevado de sulfato de heparano em um indivíduo que foi o receptor de um órgão, tecido ou células transplantados

Country Status (7)

Country Link
US (1) US20160109459A1 (pt)
EP (1) EP2844278A4 (pt)
JP (1) JP2015517469A (pt)
BR (1) BR112014027333A2 (pt)
CA (1) CA2872104A1 (pt)
MX (1) MX2014013049A (pt)
WO (1) WO2013166163A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201603059YA (en) 2012-05-09 2016-05-30 Cantex Pharmaceuticals Inc Treatment Of Myelosuppression
WO2016133910A1 (en) 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
WO2017123549A1 (en) * 2016-01-11 2017-07-20 Cantex Pharmaceuticals, Inc. Methods of treating or preventing graft-versus-host disease using hmgb1-interacting heparinoids
CN111971561A (zh) * 2017-12-27 2020-11-20 威拓股份有限公司 同种异体移植受体分型的生物标记物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006706A1 (en) * 1990-10-16 1992-04-30 John Lezdey Treatment of inflammation
US20090118162A1 (en) * 2005-06-07 2009-05-07 Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
EP2086553A4 (en) * 2006-10-20 2010-12-29 Univ Australian INHIBITION OF EXTRACELLULAR MATRIX DEGRADATION
AU2011226755A1 (en) * 2010-03-12 2012-10-04 The Australian National University Heparan sulfate replacement therapy

Also Published As

Publication number Publication date
EP2844278A4 (en) 2015-11-04
JP2015517469A (ja) 2015-06-22
WO2013166163A1 (en) 2013-11-07
CA2872104A1 (en) 2013-11-07
US20160109459A1 (en) 2016-04-21
MX2014013049A (es) 2015-03-19
EP2844278A1 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
BRPI0921799B8 (pt) compostos que expandem células-tronco hematopoétticas
BR112015007878A2 (pt) composto compreendendo oligonucleotídeo modificado, composição, combinação e uso dos mesmos
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
BR112013002811A8 (pt) meios básicos simplificados para cultura celular pluripotente de humano
MX2016005574A (es) Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.
BR112015017174A2 (pt) preparação de enxertos de nervo de tecido manipulado com matriz extracelular modificada para reparo de lesão de nervo periférico
BR112012032979B8 (pt) Composição para limpeza da pele límpida, de baixa irritação, e com ph relativamente baixo e método de limpeza da pele
CR11723A (es) Agente para tratar enfermedad
BRPI1102843B8 (pt) Composições de limpeza límpidas, de baixa irritação com ph relativamente baixo
MY170013A (en) Methods and compositions for enhancing stem cell mobilization
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112012012476A2 (pt) "composições nutritivas incluindo um componente de alta proteína e nucleotídeos exôgenos"
MX2019008872A (es) Prevencion y tratamiento de da?o o enfermedad osea y cartilago.
BR112014027333A2 (pt) composição, métodos de tratamento ou melhora, de prevenção, e, de diagnóstico de uma condição prejudicial que está associada com o teor elevado de sulfato de heparano em um indivíduo que foi o receptor de um órgão, tecido ou células transplantados
BR112018067434A2 (pt) partículas de microagulha, composições e métodos de tratamento e entrega de uma substância de interesse
BR112015010266A2 (pt) método e dispositivo para intensificação de nível de cinza
BR112015032570A2 (pt) lipoenchimento com células-tronco derivadas de tecido adiposo expandidas ex vivo para preenchimento de mama estético ou para preenchimento e/ou rejuvenescimento facial
BRPI0612424A2 (pt) composiÇÕes e mÉtodos para tratar condiÇÕes relacionadas com a sinalizaÇço da efrina com cupredoxinas
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
BR112013016809A2 (pt) composições de hidratação celular
TR201811308T4 (tr) Kanser kok hücrelerini azaltan anti-emp2 tedavisi.
CR20110226A (es) Composición para tratar enfermedad
MX2015017555A (es) Metodos y composiciones para aumentar la movilizacion de las celulas madre.
BR112015023205A2 (pt) composições e métodos para formulações de alfavírus vivo atenuado
BR112015020178A2 (pt) composição com propriedades de inflamação reduzidas para pele biológica e método de redução da inflamação do tecido biológico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2512 DE 26-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.